- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
78 result(s) found for: Color therapy.
Displaying page 1 of 4.
EudraCT Number: 2016-003856-59 | Sponsor Protocol Number: MGT007 | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:MeiraGTX UK II Ltd | |||||||||||||
Full Title: Long-term follow-up study of participants following an open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/8-hCARp.hCNGB3) for gene thera... | |||||||||||||
Medical condition: Achromatopsia caused by mutations in the CNGB3 gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001266-26 | Sponsor Protocol Number: GS-LHON-CLIN-03B | Start Date*: 2016-01-21 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months a... | ||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000080-85 | Sponsor Protocol Number: 17-245 | Start Date*: 2018-11-29 | |||||||||||
Sponsor Name:CHU CAEN | |||||||||||||
Full Title: Pilot study of the pharmacokinetic profile of paracetamol subcutaneously versus intravenously in patients receiving palliative care | |||||||||||||
Medical condition: Major patients in palliative care | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005383-22 | Sponsor Protocol Number: Kognition | Start Date*: 2022-07-27 |
Sponsor Name:Universitätsmedizin Göttingen | ||
Full Title: Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) | ||
Medical condition: Iron deficiency in patients with chronic heart failure and mild cognitive impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001265-11 | Sponsor Protocol Number: GS-LHON-CLIN-03A | Start Date*: 2016-01-21 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by... | ||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020220-22 | Sponsor Protocol Number: H6D-MC-LVIR | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Be... | |||||||||||||
Medical condition: Benign Prostatic Hyperplasia (BPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004946-13 | Sponsor Protocol Number: IIS40942 | Start Date*: 2013-09-30 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Impact of timolol/dorzolamide therapy on autoregulation in glaucoma patients | ||
Medical condition: Primary open-angle glaucoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-002947-41 | Sponsor Protocol Number: N19PCA | Start Date*: 2019-11-20 |
Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek | ||
Full Title: Neoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma (PROPANGIO). | ||
Medical condition: Angiosarcoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002249-11 | Sponsor Protocol Number: BLQ-01-003-04 | Start Date*: 2004-09-20 |
Sponsor Name:BAUSCH&LOMB - IOM S.P.A. | ||
Full Title: Double blind, randomized, multicenter, placebo-controlled, parallel-group design clinical trial of the efficacy and tolerability of cloriclomene hydrochloride capsules 100 mg TID in diabetic patien... | ||
Medical condition: Mild to moderate non-proliferative diabetic retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-003604-40 | Sponsor Protocol Number: AFT-RAP-01 | Start Date*: 2023-03-21 | |||||||||||
Sponsor Name:AFT Pharmaceuticals Ltd. | |||||||||||||
Full Title: Rapamycin Dose-Ranging Efficacy Study: A Phase II, proof of concept, double-blind, placebo-controlled, randomized, parallel-group, dose-response comparison of the effects of different strengths of ... | |||||||||||||
Medical condition: Subjects diagnosed with port wine stains | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004547-77 | Sponsor Protocol Number: RN03-CP-0001 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:ReNeuron Ltd | |||||||||||||
Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) | |||||||||||||
Medical condition: Retinitis Pigmentosa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022284-35 | Sponsor Protocol Number: R00002 CR 301 (ORF) | Start Date*: 2011-03-08 | |||||||||||
Sponsor Name:ORFAGEN | |||||||||||||
Full Title: CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI) | |||||||||||||
Medical condition: Lamellar Ichthyosis (LI) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) DE (Completed) FR (Ongoing) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005184-13 | Sponsor Protocol Number: 50129 | Start Date*: 2017-11-29 |
Sponsor Name:MEDIOLANUM FARMACEUTICI S.P.A. | ||
Full Title: METRO STUDY - MESOGLYCAN VERSUS PLACEBO IN SECONDARY PREVENTION OF SURFACE VEIN THROMBOSIS | ||
Medical condition: patients with SVT of the lower limbs that have completed the acute phase treatment cycle | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001856-19 | Sponsor Protocol Number: MRVT-920101-OPH005 | Start Date*: 2005-10-24 |
Sponsor Name:Miravant Pharmaceuticals, Inc. | ||
Full Title: A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex™ (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal... | ||
Medical condition: classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004750-21 | Sponsor Protocol Number: TAK-935-2008 | Start Date*: 2019-06-10 | ||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda | ||||||||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional... | ||||||||||||||||||
Medical condition: Complex Regional Pain Syndrome (CRPS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003874-30 | Sponsor Protocol Number: ATILA-ictus-2021 | Start Date*: 2022-02-21 | |||||||||||||||||||||||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI). | |||||||||||||||||||||||||||||||||
Full Title: RANDOMIZED MULTI-CENTER CLINICAL TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF TIROFIBAN VERSUS INTRAVENOUS ASPIRIN IN PATIENTS WITH ACUTE ISCHEMIC STROKE SECONDARY TO TANDEM INJURY, SUBJECT TO R... | |||||||||||||||||||||||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002826-70 | Sponsor Protocol Number: A3671008 | Start Date*: 2005-11-28 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017, USA | |||||||||||||
Full Title: A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma | |||||||||||||
Medical condition: Malignant Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004934-14 | Sponsor Protocol Number: EMASPK01 | Start Date*: 2014-01-15 | ||||||||||||||||
Sponsor Name:Institut klinické a experimentální medicíny | ||||||||||||||||||
Full Title: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY | ||||||||||||||||||
Medical condition: simultaneous pancreas/kidney allograft transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005228-10 | Sponsor Protocol Number: TG-MV-008 | Start Date*: 2008-10-03 | |||||||||||
Sponsor Name:ThromboGenics NV | |||||||||||||
Full Title: An Open Label, Single Center Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion | |||||||||||||
Medical condition: Focal vitreomacular adhesion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001004-22 | Sponsor Protocol Number: CRH 06/374/M | Start Date*: 2008-07-09 | |||||||||||
Sponsor Name:Centre René Huguenin | |||||||||||||
Full Title: A multicentre phase II trial to determine the efficacy of the anti-tyrosine kinase sunitinib (SUTENT®) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium wh... | |||||||||||||
Medical condition: Histologically proven advanced TCC (transitional cell carcinoma) of the urothelium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
